INTELLIA THERAPEUTICS, INC. (NASDAQ:NTLA) Files An 8-K Results of Operations and Financial ConditionItem 2.02.
| Item 2.02. | Financial Statements and Exhibits. |
(d) Exhibits
| 99.1 | Press release dated August1, 2017 |
Intellia Therapeutics, Inc. ExhibitEX-99.1 2 d434926dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Intellia Therapeutics Announces Second Quarter 2017 Financial Results • In non-human primates,…To view the full exhibit click here
About INTELLIA THERAPEUTICS, INC. (NASDAQ:NTLA)
Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company’s sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. The Company’s division, eXtellia Therapeutics, is focused on the application of CRISPR/Cas9 genome editing in the fields of immuno-oncology and autoimmune and inflammatory diseases. The Company’s subsidiary is Intellia Securities Corp. As of September 30, 2016, the Company had not generated any revenue.
